We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Ozurdex (dexamethasone)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Ozurdex (dexamethasone)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Ozurdex is an intravitreal implant containing 0.7 mg (700 µg) dexamethasone in the Novadur solid polymer drug delivery system. Dexamethasone, a potent corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

    Ozurdex is specifically indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

    Ozurdex is supplied as an 0.7 mg implant for intravitreal injection.

    Clinical Results

    FDA Approval
    The FDA approval of Ozurdex was based on the results of two, multicenter, double-masked, randomized, parallel studies. Following a single injection of Ozurdex, the following clinical results for the percent of patients with ≥ 15 letters of improvement from baseline in best-corrected visual acuity (BCVA):

    Study One (n=403)

  • Day 30: 20% for the Ozurdex arm vs. 7% for placebo (p<0.01)
  • Day 60: 29% vs. 10% (p<0.01)
  • Day 90: 22% vs.(12% (p<0.01)
  • Day 180: 19% vs. 18% (p= 0.780)
  • Study Two (n=450)

  • Day 30: 23% for the Ozurdex arm vs. 8% for placebo (p<0.01)
  • Day 60: 30% vs. 12% (p<0.01)
  • Day 90: 21% vs.14% (p=0.039)
  • Day 180: 24% vs. 17% (p=0.087)
  • In each individual study and in a pooled analysis, time to achieve ≥15 letters (3-line) improvement in BCVA cumulative response rate curves were significantly faster with Ozurdex compared to sham (p< 0.01). The onset of a ≥ 15 letter (3 line) improvement in BCVA with Ozurdex occurs within the first two months after implantation in approximately 20-30% of subjects. The duration of effect persists approximately one to three months after onset of this effect.

    Side Effects

    Adverse events associated with the use of Ozurdex may include, but are not limited to, the following:

    • Intraocular pressure increased
    • Conjunctival hemorrhage
    • Eye pain
    • Conjunctival hyperemia
    • Ocular hypertension
    • Cataract
    • Vitreous detachment
    • Headache

    Mechanism of Action

    Ozurdex is an intravitreal implant containing 0.7 mg (700 µg) dexamethasone in the Novadur solid polymer drug delivery system. Dexamethasone, a potent corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

    Literature References

    Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009 Jan;29(1):46-51

    Fialho SL, Behar-Cohen F, Silva-Cunha A Dexamethasone-loaded poly(epsilon-caprolactone) intravitreal implants: a pilot study. European Journal of Pharmaceutics and Biopharmaceutics 2008 Mar;68(3):637-46

    Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Archives of Ophthalmology 2007 Mar;125(3):309-17

    Fialho SL, Rêgo MB, Siqueira RC, Jorge R, Haddad A, Rodrigues AL, Maia-Filho A, Silva-Cunha A Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Current Eye Research 2006 Jun;31(6):525-34

    Additional Information

    For additional information regarding Ozurdex or macular edema following branch retinal vein occlusion or central retinal vein occlusion, please visit the Ozurdex web page.

    Approval Date: 2009-06-01
    Date Created: 2009-06-24 12:00:00
    Company Name: Allergan
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing